SCHEMBL16048726

SCHEMBL16048726

Cc1ccc2c(c1)C(=O)C(=O)N2CC(C)C

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.60
MAPT P10636 7/20 0.58
TP53 P04637 2/20 0.58
ACHE P22303 3/20 0.57
KMT2A Q03164 5/20 0.56
MEN1 O00255 4/20 0.56
LMNA P02545 4/20 0.56
POLB P06746 3/20 0.56
RCE1 Q9Y256 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
HSP90AA1 P07900 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
PDE5A O76074 1/20 0.50
KDM4E B2RXH2 1/20 0.50
AGTR1 P30556 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20248922 0.86 ALDH1A1 (0.49) ALDH1A1MAPTTP53ACHEKMT2A
SCHEMBL16046485 0.84 ALDH1A1 (0.60) ALDH1A1MAPTTP53ACHEKMT2A
SCHEMBL16048451 0.83 ALDH3A1 (0.60) ALDH1A1MAPTTP53ACHE
SCHEMBL22667216 0.83 CUL4A (0.62) ALDH1A1MAPTTP53ACHE
SCHEMBL12930230 0.83 PARK7 (0.69) ALDH1A1
SCHEMBL30403478 0.83 CUL4A (0.62) ALDH1A1MAPTTP53ACHE
SCHEMBL16045745 0.82 ALDH1A1 (0.64) ALDH1A1MAPTTP53ACHEKMT2A
SCHEMBL396957 0.81 PARK7 (0.68) ALDH1A1MAPTTP53ACHEKMT2A
SCHEMBL29862307 0.81 PARK7 (0.68) ALDH1A1MAPTTP53ACHEKMT2A
SCHEMBL7293785 0.80 ACHE (0.60) ALDH1A1MAPTTP53ACHEKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10253035-B2 Eis inhibitors UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2019-04-09 US disclosed
US-20180162867-A1 EIS INHIBITORS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2018-06-14 US disclosed
US-9920029-B2 Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2018-03-20 US disclosed
US-9920029-B2 Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2018-03-20 US disclosed
US-9920029-B2 Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2018-03-20 US disclosed
EP-2970183-A2 ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS Musc Foundation for Research Development (US) 2016-01-20 EP disclosed
US-20150218128-A1 Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders MUSC Foundation for Research Development (10 pp.) 2015-08-06 US disclosed
US-20150218128-A1 Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders MUSC Foundation for Research Development (10 pp.) 2015-08-06 US disclosed
US-20150218128-A1 Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders MUSC Foundation for Research Development (10 pp.) 2015-08-06 US disclosed
US-9079853-B2 Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2015-07-14 US disclosed
US-9079853-B2 Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2015-07-14 US disclosed
US-9079853-B2 Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2015-07-14 US disclosed
WO-2014160143-A2 ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2014-10-02 WO disclosed
US-20140275075-A1 ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2014-09-18 US disclosed
US-20140275075-A1 ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2014-09-18 US disclosed
US-20140275075-A1 ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218128-A1 Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders CLN6, AREG, HASPIN ALDH1A1 751/4885MAPT 551/4885TP53 868/4885
US-20180162867-A1 EIS INHIBITORS EP300, ACAT1, ACAT2 ALDH1A1 1232/4885MAPT 4313/4885TP53 3189/4885
US-10253035-B2 Eis inhibitors EP300, ACAT1, ACAT2 ALDH1A1 1232/4885MAPT 4313/4885TP53 3189/4885
US-20140275075-A1 ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS CLN6, AREG, HASPIN ALDH1A1 751/4885MAPT 551/4885TP53 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.